The antiobesity and metabolic activities of LY79771 in obese and normal mice.
Without affecting the appetite, Compound LY79771 reduced the body weight of obese Avy/a mice, prevented young Avy/a mice from becoming obese and ob/ob mice from becoming overtly obese. This weight-controlling effect of LY79771 was reversible upon withdrawal of treatment. The major portion of the weight change induced by the compound was due to a reduction in triacylglycerol content of the body. Hyperinsulinemia and hyperglycemia of the obese mice were also improved. In spite of its potent lipolytic activity, only a 20 to 25 per cent excess of fatty acid was found in the liver after dosing. No accumulation of fatty acid was observed in the carcass. A single dose of LY79771 also stimulated metabolism as indicated by the increase of CO2 expiration. The transient rise of body temperature that occurred after each injection in a long-term treatment regimen suggested that the compound was thermogenic. LY79771 had no effect on the weight of normal mice.
D015078:2-Hydroxyphenethylamine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001831:Body Temperature / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005260:Female; D007328:Insulin / Q000097:blood; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese / Q000378:metabolism*; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D009929:Organ Size; D010627:Phenethylamines / Q000627:therapeutic use*; D011506:Proteins / Q000378:metabolism; D013997:Time Factors; D014280:Triglycerides / Q000378:metabolism
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D010627:Phenethylamines; D011506:Proteins; D014280:Triglycerides; D015078:2-Hydroxyphenethylamine; C033231:LY 79771